Frontiers in Cardiovascular Medicine (Nov 2022)

Ultra-high-resolution assessment of lesion extension after cryoballoon ablation for pulmonary vein isolation

  • Francesco Spera,
  • Maria Lucia Narducci,
  • Gianluigi Bencardino,
  • Francesco Perna,
  • Antonio Bisignani,
  • Gaetano Pinnacchio,
  • Claudio Tondo,
  • Ruggero Maggio,
  • Giuseppe Stabile,
  • Giuseppe Stabile,
  • Saverio Iacopino,
  • Fabrizio Tundo,
  • Anna Ferraro,
  • Antonio De Simone,
  • Maurizio Malacrida,
  • Federico Pintus,
  • Filippo Crea,
  • Gemma Pelargonio

DOI
https://doi.org/10.3389/fcvm.2022.985182
Journal volume & issue
Vol. 9

Abstract

Read online

IntroductionUnrecognized incomplete pulmonary vein (PV) isolation during the index procedure, can be a major cause of clinical recurrences of atrial fibrillation (AF) after cryoballoon (CB) ablation. We aimed to characterize the extension of the lesions produced by CB ablation and to assess the value of using an ultra-high resolution electroanatomic mapping (UHDM) system to detect incomplete CB lesions.Materials and methodsTwenty-nine consecutive patients from the CHARISMA registry undergoing AF ablation at four Italian centers were prospectively evaluated. The Rhythmia™ mapping system and the Orion™ (Boston Scientific) mapping catheter were used to systematically map the left atrium and PVs before and after cryoablation.ResultsA total of 116 PVs were targeted and isolated. Quantitative assessment of the lesions revealed a significant reduction of the antral surface area of the PV, resulting in an ablated area of 5.7 ± 0.7 cm2 and 5.1 ± 0.8 cm2 for the left PV pair and right PV pair, respectively (p = 0.0068). The mean posterior wall (PW) area was 22.9 ± 2 cm2 and, following PV isolation, 44.8 ± 6% of the PW area was ablated. After CB ablation, complete isolation of each PV was documented by the POLARMap™ catheter in all patients. By contrast, confirmatory UHDM and the Lumipoint™ tool unveiled PV signals in 1 out of 114 of the PVs (0.9%). Over 30-day follow-up, no major procedure-related adverse events were reported. After a mean follow-up of 333 days, 89.7% of patients were free from arrhythmia recurrence.ConclusionThe lesion extension achieved by the new CB ablation system involved the PV antrum, with less than 50% of the PW remaining untouched. The new system, with short tip and circular mapping catheter, failed to achieve PV isolation in only 0.9% of all PVs treated.Clinical trial registration[http://clinicaltrials.gov/], identifier [NCT03793998].

Keywords